Kasia Siwek, Sanofi's country medical head for Australia and NZ, said, “At Sanofi, we are proud of our ongoing work with both the Australian clinical community and the government to broaden access to LIBTAYO as a first-line treatment for eligible Australians diagnosed with metastatic NSCLC. …
Sanofi welcomes new lung cancer listing for immune checkpoint inhibitor
April 4, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Roche announces historic investment to build US manufacturing base
April 23, 2025 - - Latest News -
'Reflecting the experience of people living with cancer, Pfizer’s new campaign Part of the Story seeks to reshape the narrative'
April 23, 2025 - - Latest News -
US trade agenda looks mostly disinterested in pharmaceuticals
April 23, 2025 - - Latest News -
Mesoblast says Ryoncil payer coverage extended to over 100 million Americans
April 22, 2025 - - Australian Biotech -
Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial
April 22, 2025 - - Australian Biotech -
Recce Phase 2 trial receives additional approval for treating diabetic patients with topical gel
April 22, 2025 - - Australian Biotech -
Race says patient enrolment opened at second site for RC220 solid tumour trial
April 22, 2025 - - Australian Biotech